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Identity 
Note: Most of the recurrent abnormalities in T-ALL are 
different from those associated with B-lineage ALL. 
Clinical aspects of the main chromosomal 
abnormalities observed by conventional cytogenetics 
are herein described. The numerous oncogenes 
involved in T-ALL were first characterized by cloning 
of recurrent chromosomal abnormalities. Subsequently, 
distinct oncogenic T-ALL subgroups were defined by 
modern molecular methods. A brief description of the 
novel cryptic genetic lesions that are intertwined with 
the molecular cytogenetics of T-cell disease is 
presented here. 
Other names: T-cell ALL 
Clinics and pathology 
Etiology 
Immunophenotypic and gene expression analyses of T-
ALL cells have revealed heterogeneity that is partially 
related to arrest at distinct stages of development. 
Initial cytogenetics studies of T-ALL cases showed 
nonrandom breakpoints within the following three T-
cell receptor (TCR) gene clusters: TRA@(TCRA), 
TRD@(TCRD) locus (14q11.2), or TRB@(TCRB) 
locus (7q34). The TCR breakpoints were present in 
about 30% to 35% of T-ALL cases. The 
TRG@(TCRG) locus (7p14) may be restricted to T-cell 
ALL in patients with ataxia telangiectasia. During T-
cell differentiation, these four loci undergo structural 
rearrangement that is analogous to the rearrangement of 
immunoglobulin genes during B-cell development. 
The TCR promoter and enhancer elements are 
juxtaposed to a relatively small number of 
developmentally important genes that encode 
transcription factors leading to T-cell malignancies. 
The chromosomal aberrations that affect the TCR loci 
were among the first to be reported in T-ALL. 
Subsequently, these and other rarer translocations 
facilitated the identification of genes that are altered in 
T-ALL, many of which are also transcriptionally 
activated without evidence of any detectable 
chromosomal rearrangement affecting these loci. In 
summary, the ectopic expression of TAL1(SCL), 
LYL1, LMO1, LMO2, TLX1(HOX11), and 
TLX3(HOX11L2), NOTCH1-activating mutations, and 
CDKN2-inactivating deletions are among the most 
prevalent causes of human T-ALL. 
Epidemiology 
Among acute leukemia, T-ALL accounts for about 15% 
of pediatric cases and 20% of adults cases. As detected 
by conventional cytogenetic methods, patients with T-
ALL have a smaller percentage of abnormal clones 
(60%-70%) than do patients with B-lineage ALL (80%-
90%). Tetraploidy is observed in about 3% of patients 
with T-ALL, but it has no known prognostic 
significance. Cytogenetic abnormalities that are 
common in B-cell ALL (e.g., high-hyperdiploidy) are 
uncommon in T-cell ALL. Many of the translocations 
seen in T-ALL are recurrent but with a low frequency. 
A high number of T-ALL cases have cryptic 
abnormalities, as shown by fluorescent in situ 
hybridization (FISH) or other molecular methods. In 
some instances, this occurs because some of the loci 
involved in oncogenic rearrangements of T-ALL have a 
near-telomeric location that generates subtle exchanges 
in DNA material, and these changes subsequently cause 
the cryptic translocations. As many as 80% of patients 
with T-ALL have cryptic deletions of the putative 
tumor suppressor gene CDKN2A(INK4A) (9p21), and 
as many as 60% have cryptic deletions of TAL1 
(1p32). Other genes such as TLX1(HOX11) (10q24) 
and NOTCH1 (9q34) are activated at a much higher 
frequency than expected from cytogenetic studies 
alone; thus, simultaneous dysregulation of different 
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signaling pathways may contribute to the multistep 
pathogenesis of T-ALL subgroups. 
Clinics 
The incidence of T-ALL increases with age, i.e., at 1 to 
10 years of age, the incidence is about 7%; at 10 to 15 
years, about 14%; and at 15 to 18 years, about 29%. T-
ALL is more common in boys and is characterized by 
hyperleukocytosis, enlarged mediastinal lymph nodes, 
and the scarcity of hyperdiploid (>50 chromosomes) 
leukemic cells. T-ALL also often involves the central 
nervous system (CNS). Children and adolescents with 
T-ALL are much more likely than children with B-
lineage ALL to meet 'high-risk' age and white blood 
cell count criteria (75% for T-ALL versus 32% for B-
precursor ALL). However, unlike that in B-precursor 
ALL, high leukocyte count does not identify high-risk 
T-ALL in children or adults. 
Prognosis 
The historically unfavorable outcome of patients with 
T-ALL has recently improved through the use of highly 
effective treatment protocols. T-ALL is now treated the 
same way as high-risk B-progenitor ALL. With 
appropriately intensive therapy, children with T-ALL 
have an outcome similar to that of children with B-
precursor ALL, i.e., the estimated 5-year event-free 
survival (EFS) is 75% to 80%. Nevertheless, patients 
with T-ALL remain at increased risk for remission 
induction failure, early relapse, and isolated CNS 
relapse. In a recent study of adolescents with ALL, no 
significant difference in outcome of T-ALL was found 
on the basis of age; older patients did as well as 
younger ones. 
At present, there are no genetic markers in T-ALL that 
reliably predict treatment response or outcome. Gene 
expression analysis has revealed the prognostic 
significance of T-ALL oncogenes and the stage of 
thymocyte differentiation in which they are expressed. 
Some genetic markers have been shown to be of 
clinical relevance in a small series of pediatric patients 
with T-ALL: TLX1(HOX11)+ was associated with 
favorable outcome, and TAL1+ and LYL1+ were 
associated with unfavorable outcome. A favorable 
prognosis was also found with TLX1(HOX11)+ in 
adult T-ALL, possibly due to downregulation of 
antiapoptotic genes. The poor prognosis associated 
with T-ALL subtypes expressing TAL1 or LYL1 is 
thought to be caused by the concomitant upregulation 
of antiapoptotic genes that confer resistance to 
chemotherapy. 
In early studies, the overexpression of 
TLX3(HOX11L2) was associated with poor prognosis; 
however, similar, more recent studies have not 
confirmed such findings. This difference is probably a 
reflection of the current aggressive treatments that have 
improved the therapeutic response in this subgroup of 
T-ALL. Therefore, the clinical significance of genetic 
lesions in T-ALL remains largely unknown. The 
prognostic significance of T-ALL subtypes most likely 
depends on the type and intensity of the treatment 
administered. The development of targeted therapy for 
T-ALL might be contentious, given the simultaneous 
presence and the high prevalence of some genetic 
lesions affecting T-ALL. 
Cytogenetics 
Note: Conventional molecular cytogenetic analyses of 
genetic lesions in T-ALL are summarized below. The 
following section presents prominent, recurring 
chromosomal abnormalities that affect either TCR or 
genes other than TCR (non-TCR genes) in T-ALL 
(Table 1). The breakpoints of some chromosomal 
rearrangements and gene names may have been 
modified from the original report for consistency and 
according to current HUGO gene nomenclature. 
Cytogenetics morphological 
TCR GENETIC LESIONS IN T-ALL 
TRB@ (7q34) 
Conventional cytogenetic analysis revealed that 
chromosomal abnormalities affecting 7q34 (TRB@) 
occur in 5% to 8% of T-ALL cases with an abnormal 
karyotype. Recent molecular cytogenetics studies have 
revealed a higher incidence of TRB@ locus 
rearrangements (about 20% of all T-ALL cases). This 
finding demonstrates that the frequency of TRB@ 
rearrangements is similar to that of TRA@ (14q11.2) 
(about 24% of all T-ALL cases). Simultaneous 
rearrangements targeting both the TRB@ and TRA@ 
loci were observed in five of 126 (4%) patients with T- 
ALL, possibly reflecting the higher susceptibility for 
errors in VDJ recombination. 
t(1;7)(p32;q34). The variant t(1;7)(p32;q34) disrupts 
TAL1 (TCL5/SCL) by juxtaposing to the TRB@ locus. 
t(1;7)(p34;q34). This rare t(1;7)(p34;q34) is present in 
less than 1% of T-ALL cases and results in the fusion 
of LCK and TRB@ loci, thereby activating LCK. 
t(7;9)(q34;q34.3). The t(7;9)(q34;q34.3) occurs in 
about 2% of T-ALL, resulting in the fusion of TRB@ 
and NOTCH1 loci. NOTCH1 is an early transcription 
factor that commits lymphoid progenitor cells toward 
T-cell development. NOTCH1-activating mutations 
have been shown in more than 50% of T-ALL cases. 
This finding suggests that NOTCH1 helps transform T-
lineage cells. One study demonstrated that NOTCH1-
activating mutations predict a more rapid, early 
treatment response and significantly better 4-year EFS 
than those without mutations (90% vs. 71%). NOTCH1 
mutations are associated with the expression of TAL1, 
LYL1, TLX1, TLX3, MLL-MLLT1, and PICALM-
MLLT10, all of which define the major subtypes of T-
ALL. 
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Table 1. Immunophenotype-specific rearrangements generated by T-cell receptor (TRC) and non-TCR genes in T-lineage acute 
lymphoblastic leukemia (T-ALL). 
 
These findings highlight the importance of the multiple 
pathways regulated by NOTCH1 signaling in the 
process of leukemogenesis. Targeted therapies directed 
toward the NOTCH1 pathway may be of potential 
clinical relevance for patients with T-ALL who carry 
such activating mutations. Furthermore, gama-secretase 
inhibitors (GSI) induce cell cycle arrest in vitro in T-
ALL cell lines harboring NOTCH1 mutations. 
Therefore, GSIs are a potential therapeutic strategy for 
the treatment of T-ALL. However, the integration of 
such targeted therapy should be implemented with 
caution because of the recently reported excellent 
treatment outcome for patients with NOTCH1-
activating mutations. 
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t(7;9)(q34;q32). The infrequent t(7;9)(q34;q32) results 
in the altered expression of TAL2. 
t(7;10)(q34;q24). A variant of the more common 
t(10;14)(q24;q11.2), t(7;10)(q34;q24) activates the 
expression of the DNA-binding transcription factor 
gene TLX1 (HOX11). 
t(7;11)(q34;p13). A variant of the more common 
t(11;14)(p13;q11.2), t(7;11)(q34;p13) activates the 
expression of the DNA-binding transcription factor 
gene LMO2. 
t(7;12)(q34;p13.3). The rare t(7;12)(q34;p13.3) 
deregulates CCND2 by chromosomal translocations to 
the TRB@ locus in T-ALL. This translocation and its 
variant, t(12;14)(p13;q11.2), are also associated with 
other genetic lesions observed in T-ALLs, a finding 
that suggests that CCND2 dysregulation contributes to 
multievent oncogenesis in various subtypes of T-ALL. 
t(7;14)(q34;q32.1)/TCL1. The variant 
t(7;14)(q34;q32.1) is also seen in T-cell leukemias, 
juxtaposing TRB@ with TCL1A. 
t(7;19)(q34;p13.2). In the t(7;19)(q34;p13.2), the 
LYL1 gene is juxtaposed to the TRB@ locus, resulting 
in the constitutive expression of LYL1, which is not 
expressed in normal T cells. Patients whose leukemic 
blast cells ectopically express LYL1 have an 
unfavorable outcome, which is thought to be due to the 
upregulation of antiapoptotic proteins. 
inv(7)(p15.3;q34)/t(7;7)(p15.3;q34). As a result of a 
cryptic inv(7)(p15q34) and t(7;7)(p15;q34), the TRB@ 
locus is juxtaposed to the HOXA@ at 7p15 in about 
3.3% of T-ALL cases. This rearrangement leads to 
transcriptional activation of several HOXA genes, 
including HOXA10 and HOXA11. One case was 
identified carrying a triplication of the TRB@-HOXA 
fusion on a ring chromosome 7; this finding suggested 
an additional mechanism of transcriptional activation of 
HOXA@. Furthermore, HOXA@ expression is 
increased in the absence of these chromosomal 
rearrangements in 25% of T-ALL cases. The 
upregulation of HOXA gene expression was also found 
in MLL-MLLT1(ENL)+ and PICALM(CALM)-
MLLT10(AF10)+ T-ALLs, a NOTCH1-activating 
mutation, and a deletion of 9p21. These findings 
indicated a more general role of HOXA@ genes in T-
cell oncogenesis. The outcome of 14 patients with the 
TRB@-HOXA@ in a larger study was similar to that 
of other patients with T-ALL who did not carry the 
fusion transcript. 
Other cryptic breakpoints. Evaluations of cryptic 
7q34/TRB@ with FISH probes include new putative 
transcription factor genes at 11q24, 20p12, and 6q22. 
The subtle rearrangements at 7q34 can be explained by 
distant chromosomal location of the TRB@ (7q34) and 
the partner gene(s). For example, the t(7;7)(p15.3;q34), 
inv(7)(p15.3q34), t(7;11)(q34;q24), and 
t(7;10)(q34;q24) all have distal breakpoints. 
 
 
TRG@ (7p14) 
The TRG@(TCRG) locus (7p14) may be restricted to 
T-cell tumors in patients with ataxia telangiectasia. The 
TRG@ locus is not involved in translocations in T-
ALL. Historically, it was thought that the 
inv(7)(p15;q34) or t(7;7)(p15;q34) juxtaposed TRB@ 
to TRG@, but recently it was shown that the TRB@-
HOXA fusion is generated by such rearrangements. 
One exception was a t(1;7)(p31-32;p13) in a 16 year-
old male patient who had precursor T-cell 
lymphoblastic leukemia/lymphoma. This 
rearrangement was identified during the evaluation of 
FISH probes to detect TCR breakpoints. It was 
speculated that the breakpoint at 1p may have involved 
the TAL1 or LCK oncogenes. 
TRA@ or TRD@ (14q11.2) 
Among the most common chromosomal abnormalities 
observed by conventional cytogenetics, those 
associated with T-ALL are chromosome 14 alterations 
in which the breakpoint is located at 14q11.2. By 
conventional cytogenetics, this abnormality represents 
about 17% of all T-ALL cases (Table 1). By molecular 
cytogenetics studies, the incidence of TRA@/TRD@ 
rearrangements is about 24% of all T-ALL cases. 
t(1;14)(p32;q11.2). This translocation is observed in 
about 3% of T-ALL. The TAL1(TCL5/SCL) gene, 
which is located on 1p32, is juxtaposed with the 
TRD@ locus. As a result of t(1;14)(p32;q11.2), TAL1 
is controlled by the regulatory elements of the TRD@, 
which results in disruption of TAL1 and its ectopic 
expression (see 1p32/TAL1(SCL) deletion below). 
t(5;14)(q35.1;q11.2). The t(5;14)(q35.1;q11.2) disrupts 
the TLX3(HOX11L2) by translocating to TRD@. 
t(7;14)(p15.1;q11.2). The cloning of T-ALL from one 
patient who carried a t(7;14)(p15.1;q11.2) showed the 
juxtaposition of HOXA@ with the TRD@ 
overexpressing HOXA genes. The leukemic cells of 
this patient also had a t(10;11)(p12;q14) /PICALM-
MLLT10. 
t(8;14)(q24.1;q11.2). This translocation is seen in 
approximately 2% of patients with T-ALL, but it is not 
restricted to the T-lineage. The t(8;14)(q24.1;q11.2) 
results in the rearrangement of the TRA@ locus with 
the MYC(CMYC) oncogene, which in turn 
dysregulates MYC transcription. The disease in these 
cases is aggressive, and the response to conventional 
therapy is poor. 
t(10;14)(q24;q11.2). The t(10;14)(q24;q11.2) and its 
variant t(7;10)(q34;q24) is seen in 5% to 10% of 
patients with T-ALL or T-cell lymphomas. These 
rearrangements are more frequent in adults than in 
children. The t(10;14) results in the translocation of 
TLX1(HOX11) (10q24) to TRA@/TRD@ (14q11.2) 
and the overexpression of TLX1. The t(10;14) can be 
detected by PCR, and a dual-color FISH probe is often 
used to detect HOX11 translocations on 10q24.  
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However, TLX1 overexpression in leukemic blasts has 
been observed in the absence of 10q24 rearrangement 
in as many as 50% of T-ALL cases. Therefore, other 
trans-acting mechanisms, e.g., disruption of gene 
silencing, may cause aberrant expression of the gene. 
The gene expression pattern of TLX1-expressing 
lymphoblasts is similar to that of early cortical 
thymocytes. Therefore, the lack of expression of 
antiapoptotic genes during this stage of thymocyte 
development (and in TLX1-expressing lymphoblasts) 
may explain why pediatric and adult patients with this 
type of lymphoblast have a highly favorable outcome. 
Other studies have not demonstrated significant 
improvement in outcome. Furthermore, activation of 
other mutant genes, including NOTCH1, is found in 
most TLX1+ T-ALL. This finding suggests that 
multiple cooperating changes lead to T-cell 
differentiation arrest. 
t(11;14)(p13;q11.2). The t(11;14)(p13;q11.2) is among 
the most common nonrandom abnormalities detected 
by conventional cytogenetic methods in T-ALL blast 
cells. This rearrangement is found in less than 10% of 
children with T-ALL. The t(11;14)(p13;q11.2) TRA@ 
or TRD@ dysregulates LMO2. A rare variant, 
t(7;11)(q34;p13), may also be found with an LMO2-
TRB@ fusion that constitutively activates the LMO2 
gene. However, high levels of LMO2 expression have 
also been reported in the absence of translocations in as 
many as 30% of T-ALL cases. This finding suggests 
that alternative mechanisms in T-ALL cells activate 
LMO2. 
t(11;14)(p15;q11.2). The t(11;14)(p15;q11.2) occurs in 
1% of patients with T-ALL. The breakpoint on 
chromosome 11 is found in one of the rhombotin-2-
related, stage-specific differentiation genes (e.g., 
LMO1). LMO1 and LMO2 are expressed in patients 
whose leukemic cells also have deregulated expression 
of TAL1 or LYL1. 
t(12;14)(p13.3;q11.2). The t(12;14)(p13.3;q11.2) 
dysregulates CCND2 by translocating it to the 
TRA@/TRD@ loci. 
t(14;14)(q11.2;q32.1) or inv(14)(q11.2q32.1). These 
chromosomal abnormalities have been detected with 
high frequency in patients with ataxia telangiectasia 
and mature T-cell leukemias but less frequently in 
patients with acute T-cell leukemias. Most cases with a 
t(14;14)(q11.2;q32.1) or inv(14)(q11.2q32.1) result in 
the rearrangement of the TRA@ or TRD@ loci with 
the TCL1A oncogene on 14q32.1 centromeric to the 
IGH@ locus (14q32.3). The variant t(7;14)(q34;q32.1) 
was also seen in T-ALL, juxtaposing TRB@ with 
TCL1A. A study to evaluate the detection of TCR 
breakpoints by FISH showed that most, but not all, 
cases with 14q11.2 breaks involve TRA@/TRD@; 
likewise, not all 14q32 breaks involve TCL1A. In that 
series, one adult T-cell leukemia/lymphoma case with a 
t(14;14)(q11.2;q32) indicated a breakpoint in BCL11B, 
which is the gene involved in the t(5;14)(q35;q32), 
generating the BCL11B-TLX3 fusion. In another study, 
the leukemic blasts of a patient with T-ALL had other 
complex chromosomal aberrations and an 
inv(14)(q11.2q32) that juxtaposed the disrupted 
BCL11B gene with TRD@. Other genes located to the 
same 14q32.1 region, centromeric to TCL1A (e.g., 
TCL1b(TML1) and TCL6 ), are activated in T-cell 
malignancies. Of note, a few cases with 
t(14;14)(q11.2;q32) and B-lineage ALL were reported 
with IGH involvement. 
t(14;21)(q11.2;q22.1). The t(14;21)(q11.2;q22.1) 
translocates OLIG2(BHLHB1) to the TRA@ locus. 
t(X;14)(q28;q11.2). The t(X;14)(q28;q11.2) is mostly 
observed in mature T-cell leukemias and dysregulates 
the MTCP1 gene. 
NON-TCR GENETIC LESIONS IN T-ALL 
del(1)(p32)/TAL1(SCL). A cryptic interstitial deletion 
of TAL1 in the chromosome region 1p32 is observed in 
as many as 30% of patients with T-ALL. The deletion 
(about 90 kb) is in the coding region of the STIL(SIL) 
gene, which is also located on 1p32, and in the 
untranslated region of the TAL1 gene, thereby placing 
the TAL1-coding region under the control of the 
STIL(SIL) promoter region and generating STIL-TAL1 
fusion transcripts. The common site-specific deletion in 
TAL1 results in its ectopic expression via illegitimate 
recombinase activity. Also, misexpression of TAL1 has 
been observed in approximately 30% of patients who 
have T-ALL but no detectable TAL1 abnormality. 
Therefore, TAL1 protein is ectopically expressed in 
leukemic blast cells in as many as 60% of patients with 
T-ALL. The 90-kb deletion in the TAL1-coding region 
can be detected by FISH, Southern blot analysis, 
genomic PCR, or RT-PCR for identification of the 
various types of fusion genes generated. It is not 
detected by conventional cytogenetics. TAL1 is 
essential for primitive hematopoiesis and adult 
erythropoiesis and megakaryopoiesis. In one study, 
patients with T-ALL whose leukemic blast cells 
ectopically expressed TAL1 had an unfavorable 
outcome, which was thought to be due to the 
upregulation of antiapoptotic proteins. However, the 
clinical relevance of TAL1 rearrangements remains 
unclear. 
t(1;3)(p32;p21). The t(1;3)(p32;p21) disrupts 
TAL1(SCL/TCL5) by juxtaposing with the TCTA 
gene. 
t(1;5)(p32;q31). The t(1;5)(p32;q31) dysregulates the 
expression of TAL1 by an unknown gene. 
t(4;11)(q21;p15.5). The t(4;11)(q21;p15.5) was 
observed in a subgroup of T-ALL whose leukemic cells 
coexpressed myeloid markers. The t(4;11) results in the 
NUP98 - RAP1GDS1 fusion. 
t(4;21)(q31;q22). A t(4;21)(q31;q22) was seen in a 12-
year-old boy with T-ALL. FISH analysis showed that 
the RUNX1(AML1/CBFA2) (21q22) gene was 
rearranged by the translocation. 
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+4. Trisomy 4 as the sole chromosomal abnormality in 
ALL has been reported in T-ALL, but it is not limited 
to this lineage of disease. The clinical implications of 
+4 remain unknown. 
t(5;14)(q35.1;q32.2). The t(5;14)(q35.1;q32.2), a 
recurrent cryptic translocation specific to T cells, has 
been observed in as many as 20% of pediatric patients 
and 13% of adults patients with T-ALL. The t(5;14) is 
not observed by conventional cytogenetics, but FISH 
probes are available for its detection. In most instances, 
the t(5;14) results in the activation of the 
TLX3(HOX11L2) homeobox gene at 5q35.1. This gene 
is activated by T-cell regulatory elements downstream 
of BCL11B(CTIP2) gene, which is located at 14q32.2 
and is highly expressed during T-cell differentiation. A 
neighboring, related homeobox gene at 5q35.1, NKX2-
5(CSX), is similarly activated in T-ALL by a rarer 
variant t(5;14)(q35.1;q32.2) or by t(5;14)(q35.1;q11.2) 
involving TRD@ locus. Ectopic expression of TLX3 
has also been identified in cases of childhood T-ALL 
without evidence of the t(5;14). A few case with 
t(5;14)/BCL11B-TLX3 fusion have also shown the 
9q34amp/NUP214-ABL1 fusion. Some studies 
reported that TLX3 overexpression was associated with 
poor prognosis, whereas other studies did not confirm 
these findings. 
t(5;7)(q35.1;q21). A variant t(5;7)(q35.1;q21) 
involving the CDK6 gene on 7q21, TLX3, and other 
cryptic rearrangements affecting TLX3 have been 
reported. 
del(6q). Cytogenetic analyses revealed that deletion of 
the q arm of chromosome 6 occurs in about 15% of T-
ALL cases. Molecular analyses revealed that this 
rearrangement occurs in 15% to 32% of cases. 
Furthermore, del(6q) is more frequent in T-ALL than in 
precursor B-lineage ALL. The crucial regions of loss of 
heterozygocity in the q arm of 6q are between 6q15 and 
6q21, but no tumor suppressor gene has yet been 
identified. Earlier studies reported that del(6q) is 
associated with an inferior early response to treatment 
and poor outcome, but no prognostic significance has 
been noted in subsequent studies. This most likely 
reflects the fact that T-ALL cases are now stratified 
into the high-risk arm of treatment protocols; thus, the 
prognostic value of del(6q) depends on the treatment. 
t(6;7)(q23;q32-36). The t(6;7)(q23;q32-36) is an 
infrequent but recurrent translocation in T-ALL. The 6q 
breakpoints established in two cases were only 150 kb 
apart. In one case, the breakpoint potentially disrupted 
or deregulated the MYB gene, and in the other case, it 
potentially disrupted the AHI1 gene. 
dup6q23/MYB. Recently, a duplication of 6q23 region 
was identified in 9 of 107 (8.4%) patients with T-ALL 
by the array comparative genome hybridization (array-
CGH) method. The commonly duplicated region 
covered the MYB gene 
del(9)(p21). Deletion or inactivation of genes located 
in close proximity on 9p21 is one of the most common 
genetic defects in T-ALL. By conventional 
cytogenetics, translocations involving 9p have been 
seen in 9% to 12% of children with ALL. However, 
FISH and other molecular methods have shown that 
homozygous deletions of CDKN2A(INK4A) [encoding 
p16(INK4a) and p14(ARF) proteins] occur in 60% to 
80% of children with T-ALL; homozygous deletions of 
CDKN2B(INK4B) (encoding p15 protein) occur in 
approximately 20% of children with T-ALL. 
Hemizygous deletion of INK4A occurs in about 10% of 
pediatric T-ALL cases, and that of INK4B occurs in 
about 15%. One study has reported inactivation of 
INK4A in 93% of T-ALL cell samples tested and that 
of INK4B in 99%. Other contiguous genes such as 
IFN1@ and MTAP can be included in the deletions; 
thus, ALL with 9p21 is a rather heterogeneous group. 
Because proteins encoded by these genes might 
influence the response to treatment, the prognosis of 
patients with 9p21-deleted T-ALL could vary 
according to the extent of the deletion. The prognostic 
significance of loss of heterozygocity of CDKN2A in 
childhood ALL remains controversial. 
9p13/PAX5. The gene involved in 9p13 abnormalities 
is PAX5; its role is unclear in leukemogenesis in T-
cells. 
t(9;12)(p24;p13). JAK2 was fused to ETV6(TEL) as a 
result of the t(9;12)(p24;p13) in a child with T-ALL. 
The role of the ETV6-JAK2 fusion gene in T-ALL 
pathogenesis was confirmed by the finding that fatal 
leukemia accompanied by preferential expansion of 
CD8+ T cells developed in mice whose lymphoid cells 
contained an ETV6-JAK2 transgene. 
t(8;9)(p22;p24). This t(8;9) formed a PCM1 -JAK2 
fusion in a patient with T-cell lymphoma. Such 
translocations have been found in other patients with 
myeloid diseases. 
9q34/ABL1. The genetic lesions affecting the ABL1 
locus generate fusion proteins that are constitutively 
phosphorylated tyrosine kinases. These kinases, which 
are described in more detail below, excessively activate 
pathways that regulate cell survival and proliferation. 
Gene-targeted therapy aimed to inhibit tyrosine kinases 
(e.g., imatinib mesylate) could improve the outcome of 
patients with ABL-fusion+ T-ALL.  
t(9;22)(q34;q11.2)/BCR-ABL1(ABL).  
The t(9;22)(q34;q11.2)/BCR-ABL1(ABL), also known 
as Philadelphia (Ph)+ ALL, is associated with the worst 
prognosis in children. It occurs in 3% to 5% of children 
and in 25% of adults with the disease. Most cases of 
Ph+ ALL are phenotypically pre-B cell lineage, but an 
international pediatric study showed that 2% had a T-
cell immunophenotype. In that series, there was no 
significant prognostic difference between Ph+ pre-B 
ALL and Ph+ T-ALL. Most cases of Ph+ T-ALL have 
an aggressive course, persistence of the clone, as 
detected by minimal residual disease (MRD), and a 
dismal prognosis. Distinguishing Ph+ T-ALL from 
chronic myelogenous leukemia (CML) with T cell-
T-lineage acute lymphoblastic leukemia (T-ALL) Raimondi SC 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2007;11(4)  334 
derived leukemic blast crisis may be challenging and of 
clinical relevance in the imatinib era. 
9q34amp/NUP214-ABL1. The 9q34 amplification 
(multiple signals of the ABL1 gene per nucleus) is a 
cryptic abnormality. Although this rearrangement is not 
detectable by conventional cytogenetics, it occurs in 
about 3% to 6% of T-ALL cases. It is detected by FISH 
using ABL1 or BCR-ABL1 probes that show a variable 
number of extrachromosomal amplified elements of the 
ABL1 locus independent of BCR in metaphase, and 
multiple signals in most interphase cells. The episomes 
contained ABL1, LAMC3, and NUP214 genes 
localized within a 500-kb region on 9q34. 
Subsequently, the circular nature of the genomic region 
from ABL1 to NUP214 was discovered; this formation 
created an extrachromosomal episomal structure that 
contains the NUP214-ABL1 fusion genes. The copy 
number of the episome may vary from cell to cell, 
increasing due to unequal segregation during cell 
division. Most karyotypes of cases with 9q34amp are 
abnormal, including some of the recurrent 
translocations seen in T-ALL. The 9q34 amp is 
associated with the deletion of CDKN2A and 
CDKN2B and ectopic expression of TLX1 or TLX3. A 
few cases with t(5;14) also had the NUP214-ABL1 
extrachromosomal episomal amplification. Of interest, 
a T-ALL case with t(5;14)/BCL11B-TLX3 fusion also 
had an amplified NUP214-ABL1 fusion inserted in the 
2q21 region. This was in addition to the normal ABL1 
signals on both 9q34 copies, without evidence of 
extrachromosomal episomal amplification. The 
NUP214-ABL1 fusion appears to be associated with 
aggressive disease and poor outcome. A recent report 
of NUP214-ABL1 in adult T-ALL did not find a 
statistically significant difference in overall survival 
when compared with that in patients lacking the fusion. 
Like BCR-ABL1, the NUP214-ABL1 fusion is a 
constitutively active tyrosine kinase with transforming 
activity in vitro. However, because of the heterogeneity 
in the genetic lesions observed in many cases, the 
response to imatinib in NUP214-ABL1+ cases should 
be evaluated with caution. Ph+ CML with 
amplification of BCR-ABL1 is resistant to imatinib. 
9q34dup/amp. Recently, a duplication of 9q34 region 
was identified in 33% of pediatric T-ALL cases by 
array-CGH. The exact size of the amplified region 
differed slightly among patients, but the crucial region 
encompassed many genes such as NOTCH1 that were 
distal from ABL1 and NUP214. The size of the 9q34-
amplified region varied among patients, and in some 
cases, it was observed as only a minor leukemic clone. 
The duplication appears to be an independent genetic 
event from both the episomal NUP214-ABL1 
amplification and the NOTCH1 mutations but may lead 
to the activation of other putative regulatory genes in 
the 9q34 region. Some of the patients with the 9q34dup 
also had NUP214-ABL1 episomal amplification but in 
an independent leukemic clone. The subclones with the 
9q34dup were also observed in patients with other 
clonal abnormalities frequently seen in T-ALL cases. 
At present, the meaning of this finding is unclear. 
t(9;12)(q34;p13). Another ABL1 fusion seen in a T-
cell ALL case is t(9;12)(q34;p13), which generates the 
ETV6-ABL1 fusion. 
t(9;14)(q34;q32). A cryptic t(9;14)(q34;q32) was seen 
in one T-ALL case. This rearrangement resulted in 
EML1 -ABL1 fusion with dysregulated tyrosine kinase 
activity. The leukemic cells from this patient also 
showed ectopic expression of TLX1 and hemizygous 
deletion of the CDKN2A. Subsequently, the patient 
experienced T-ALL relapse with no evidence of the 
EML1-ABL1 but newly acquired NUP214-ABL1 
positivity. 
t(10;11)(p12;q14). The PICALM(CALM)-
MLLT10(AF10) fusion gene is created by the 
t(10;11)(p12;q14), which is a recurrent abnormality in 
about 4% to 9% of T-ALL cases. However, this 
rearrangement also has been observed in non-T-cell 
acute leukemias. The translocation is not always 
evident by conventional cytogenetic methods, but it can 
be detected by FISH or RT-PCR. Furthermore, 
distinction of this chromosomal abnormality from 
t(10;11)(p12;q23) involving MLL-MLLT10(AF10) can 
be challenging, often requiring FISH or RT-PCR to 
make the differential diagnosis. Some T-ALL cases 
with the PICALM-MLLT10 fusion also demonstrate 
upregulation of the HOXA@ genes. 
t(10;11)(q25;p15.5). This t(10;11)(q25;p15.5) was 
seen in a patient with T-ALL whose leukemic cells 
expressed myeloid markers. The rearrangement 
resulted in the NUP98- ADD3 fusion. 
del(11)(p12p13)/LMO2. A cryptic deletion of 11p was 
detected recently by array-CGH in about 4% of 
pediatric patients with T-ALL. The localization of 
genomic breakpoints in the deletion was 
heterogeneous. In most del(11p) cases, the oncogene 
LMO2 was activated independent from other recurrent 
cytogenetic abnormalities that are frequently present in 
T-ALL. In one of six patients, the RAG2 promoter 
controlled the expression of LMO2, thereby generating 
a RAG2-LMO2 fusion. In other cases, the deletion of 
negative regulatory sequences upstream of LMO2 was 
suggested to contribute to its ectopic expression. 
11p13/LMO2 - Insertional Mutagenesis. T-ALL 
developed in two of 10 infants enrolled in the retroviral 
IL2RG gene therapy trial for X-linked severe combined 
immunodeficiency (X1-SCID). Retroviral insertion in 
the proximity of the LMO2 gene leads to aberrant 
transcription and expression of LMO2. In that trial, 
leukemia was diagnosed 3 years after the gene therapy 
was completed. 
11q23/MLL. Abnormalities of 11q23 have been 
observed in approximately 4% of children with T-ALL 
and in 6% to 8% of adults with the disease. In an 
international collaborative study of ALL with 11q23 
abnormality and known immunophenotype, T-ALL 
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was present in 40 of 459 (8.7%) cases. Most patients 
with T-ALL and 11q23 rearrangements have a 
t(11;19)(q23;p13.3), though cases with a del(11)(q23) 
should be further evaluated by FISH using the MLL 
probe to rule-out a subtle translocation such as 
t(6;11)(q27;q23). Other translocations seen 
infrequently in T-ALL include (4;11)(q21;q23), 
t(9;11)(p22;q23), t(10;11)(p12;q23), and others seen in 
B-lineage ALL or AML. MLL fusion proteins have 
increased transcriptional activity; thus, these proteins 
can also cause increased expression of HOXA9, 
HOXA10, HOXC6, and the MEIS1 HOX coregulator. 
T-ALL cells with MLL fusions are characterized by 
differentiation arrest at an early stage of thymocyte 
differentiation. Despite the historical, relatively adverse 
outcome generally associated with T-ALL, those cases 
with MLL aberrations have a much better prognosis 
than do their 11q23+ B-lineage counterparts. 
t(11;18)(p15.5;q12). The t(11;18)(p15.5;q12) was 
observed in a 9 year-old boy with T-ALL. The t(11;18) 
results in the NUP98-SETBP1 fusion. 
t(11;19)(q23;p13.3). T-ALL with t(11;19)(q23;p13.3) 
results in the MLL-MLLT1(ENL) fusion, which is 
associated with a good prognosis. 
Summary:  
In addition to conventional cytogenetic studies, 
molecular techniques that are more reliable, rapid, and 
sensitive are needed to detect multiple genetic lesions 
associated with T-ALL. The improved characterization 
of T-ALL genetic subgroups may facilitate the 
development of targeted gene therapy for those patients 
with refractory disease and less toxic therapy for those 
with responsive disease. 
In recent years, the introduction of more intensive 
therapy has improved the overall outcome of patients 
with T-ALL, as indicated in the following landmark 
discoveries: Most of the recurrent abnormalities in T-
ALL are different from those associated with B-lineage 
ALL. 
- In B-lineage ALL, certain chromosomal subgroups 
have strong prognostic association. In contrast and with 
a few exceptions, cytogenetic features have no 
predictive value in T-ALL. 
- Most cases of Ph+ T-ALL have an aggressive course 
and poor prognosis, similar to those of Ph+ B-lineage 
ALL. 
- Cases of T-ALL with MLL aberrations have a much 
better prognosis than do their 11q23+ B-lineage 
counterparts. 
- The t(10;14)(q24;q11.2) or upregulation of 
TLX1(HOX11) appears to be associated with better 
prognosis. 
- Treatment outcome for patients with a NOTCH1-
activating mutation is typically good. 
- Tetraploidy is observed in about 3% of T-ALL and 
has no known prognostic significance. 
- Hyperdiploidy (>50 chromosomes), which is seen in 
25% to 30% of children with ALL, is rarely observed 
in T-ALL. 
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